Advocacy intelligence hub — real-time data for patient organizations
Idamycin: FDA approved
Therapy related acute myeloid leukemia and myelodysplastic syndrome
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Idamycin
Adria Laboratories, Inc.
Idamycin
(Idarubicin HCl for injection)Orphan drugAdria Laboratories, Inc.
12.1 Mechanism of Action Idarubicin hydrochloride has antimitotic and cytotoxic activity through forming complexes with the DNA, inhibiting nucleic ac...
Tibsovo
(IVOSIDENIB)Orphan drugstandardServier Pharmaceutical LLC
Isocitrate Dehydrogenase 1 Inhibitor [EPC]
12.1 Mechanism of Action Ivosidenib is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. In patients with A...
Browse all Therapy related acute myeloid leukemia and myelodysplastic syndrome news →
Farid Boulad, MD, MD
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Amanda Olson
M.D. Anderson Cancer Center
Jorge Cortes
M.D. Anderson Cancer Center
Guido Marcucci, M.D
Ohio State University
📍 DUARTE, CA
Roland Walter, MD PhD
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
View all Therapy related acute myeloid leukemia and myelodysplastic syndrome specialists →